Changes in ticlopidine utilization pattern after educational intervention

Chinese Pharmaceutical Journal

Volumn 51, Issue 5, 1999, Pages 347-358

  Yang, Yea Huei Kao ^a   Chen, Li Chia ^a   Chan, Kin Wei A ^b   Lai, Ming Liang ^c  

^a NATIONAL CHENG KUNG UNIVERSITY   (Taiwan)

^b NATIONAL TAIWAN UNIVERSITY   (Taiwan)

^c NATIONAL CHENG KUNG UNIVERSITY   (Taiwan)

Author keywords

Antiplatelet agent; Drug utilization evaluation; Prescribing behavior; Ticlopidine

Indexed keywords

ACETYLSALICYLIC ACID; LICODIN; TICLOPIDINE; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; CEREBROVASCULAR ACCIDENT; DRUG UTILIZATION; FEMALE; HEALTH EDUCATION; HUMAN; MAJOR CLINICAL STUDY; MALE; NEUTROPENIA; PATIENT COMPLIANCE; PRESCRIPTION; THROMBOSIS;

EID: 0033390573     PISSN: 10161015     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (33)

1. Gent M.; Blakely J. A.; Easton J. D. et al. The Canadian American Ticlopidine Study (CATS) in Thromboembolic Stroke. Lancet 1989, 1, 1215-1220.
2. Hass W. K.; Easton J. D.; Adams H. P. A Randomized Trial Comparing Ticlopidine Hydrochloride with Aspirin for the Prevention of Stroke in High-risk Patients. N. Eng. J. Med. 1989, 321, 501-507.
3. Janzon L.; Bergqvist D.; Boberg J. et al. Prevention of Myocardial Infarction and Stroke in Patients with Intermittent Claudication; Effects of Ticlopidine. Results from STIMS, the Swedish Ticlopidine Multicentre Study. J. Intern. Med. 1990, 227, 301-308.
4. Balsano F.; Rizzon P.; Violi F. et al. Antiplatelet Treatment with Ticlopidine in Unstable Angina: A Controlled Multicenter Clinical Trial. Circulation 1990, 82, 17-261.
5. Carlson J. A.; Maesner J. E. Fetal Neutropenia and Thrombocytopenia Associated with Ticlopidine. Ann. of Pharmacother. 1994, 28, 1236-1238.
6. Farver D. K.; Hansen L. A. Delayed Neutropenia with Ticlopidine. Ann. of Pharmacother. 1994, 28, 1344-1346.
7. Mallet L.; Mallet J. Ticlopidine and Fetal Aplastic Anemia in an Elderly Women. Ann. of Pharmacother. 1994, 28, 1169-1171.
8. Ruiz-Irastoza G.; Alonso J. J.; Iglesias J. J. et al. Granulocyte Colony-stimulating Factor for Neutropenia Secondary to Ticlopidine. Acta Haemat. 1994, 91, 106-107.
9. Young N. S. Agranulocytosis. J. Ame. Med. Assoc. 1994, 271, 603-605.
10. Oster G.; Huse D. M.; Lacey M. J. et al. Cost-effectiveness of Ticlopidine in Preventing Stroke in High-risk Patients. Stroke 1994, 25, 1149-1156.
11. Flores-Runk P.; Raasch R. H. Ticlopidine and Antiplatelet Therapy. Ann. Pharmacother. 1993, 27, 1090-1098.
12. Ito M. K.; Smith A. R.; Lee M. L. Ticlopidine: A New Platelet Aggregation Inhibitor. Clin. Pharm. 1992, 11, 603-617.
13. Haynes R. B.; Sandler R. S.; Larson E. B. et al. A Critical Appraisal of Ticlopidine, a New Antiplatelet Agent. Arch Intern. Med. 1992, 152, 1376-1380.
14. Su C. C.; Tseng C. D.; Hwang J. J. et al. Severe Aplastic Anemia Induced by Ticlopidine: Report of a Case. J Formosa Med. Assoc. 1995, 94, 689-691.
15. Yeh S. P.; Hsueh E. J.; Wu H. et al. Ticlopidine-associated Aplastic Anemia. A Case Report and Review of Literature. Ann. of Hemat. 1998, 75, 87-90.
16. Kao T. W.; Hung C. C.; Chen Y. C. et al. Ticlopidine-induced Aplastic Anemia: Report of Three Chinese Patients and Review of the Literature. Acta Haemat. 1997, 98, 211-213.
17. Dunn P. Aplastic Anemia with Ticlopidine Therapy in Two Chinese Patients. Ann. of Pharmacother. 1996, 30, 547.
18. Serradell J.; Bjornson D. C.; Hartzema A. G. Drug Utilization Study Methodologies: National and International Perspectives. Drug Intell. Clin. Pharm. 1987, 21, 994-1001.
19. Williams B. R. Conducting Drug-use Evaluation in Long-term Care Facilities. Consult. Pharm. 1992, 7(suppl B), 4-14.
20. Lipton H. L.; Bird J. A. Drug Utilization Review: State of the Art from an Academic Perspective. Clin. Pharmacol. Ther. 1991, 50, 616-619.
21. Lipton H. L.; Bird J. A. Drug Utilization Review in Ambulatory Settings: State of the Science and Directions for Outcomes Research. Med. care 1993, 31, 1069-1082.
22. Kao Yang Y. H.; Yang H. C. Drug Utilization Review of Essential Amino Acid Injection. J. Clin. Pharm, Assoc. 1994, 3, 91-98.
23. Fudge K. A.; Moore K. A.; Schneider D. N. et al. Change in Prescribing Patterns of Intravenous Histamine-2-receptor Antagonists Results in Significant Cost Savings without Adversely Affecting Patient Care, Ann. Pharmacother. 1993, 27, 232-237.
24. Armstrong E. P.; Terry A. K. Impact of Drug Use Evaluatin Upon Ambulatory Pharmacy Practice. Ann. Pharmacother. 1992, 26, 1546-1553.
25. Lesar T.; Belemjian M.; Harrison C. et al. Program for Controlling the Use of Ondansetron Injection. Am. J. Hasp. Pharm. 1994, 51, 3054-3056.
26. Schumock G. T.; Meek P. D.; Ploetz P. A. et al. Economic Evaluations of Clinical Pharmacy Services - 1988-1995. Pharmacother. 1996, 16, 1188-1208.
27. Soumerai S. B.; McLaughlin T. J.; Avorn J. Improving Drug Prescribing in Primary Care - a Critical Analysis of the Experimental Literature. Milbank. Q. 1989, 67, 268.
28. Schaffner W.; Wayne A. R.; Federspiel C. F. et al. Improving Antibiotic Prescribing in Office Practice. A Controlled Trial of Three Educational Methods. J. Ame. Med. Assoc. 1983, 250, 1728.
29. Avorn J.; Soumerai S. B. Improving Drug-therapy Decisions Through Educational Outreach. A Randomized Controlled Trial of Academically Base "Detailing". N. Engl. J. Med. 1983, 308, 1457.
30. Hsu V. D. Criteria for Use of Ticlopidine in Adult Inpatients and Outpatients. Clin. Pharm. 1993, 12, 64-66.
31. Jones J. K. A View from the Drug Utilization Review Management Organization Sector. Clin. Pharmacol. Ther. 1991, 50, 620-625.
32. Avorn J. Intervention: The Use of Drug Utilization Review Outcomes. Clin. Pharmacol. Ther. 1991, 50, 633-635.
33. Schectman J. M.; Kanwal N. K.; Schroth W. S. et al. The Effect of an Education and Feedback Intervention on Group-model and Network-model Health Maintenance Organization Phy-sician Prescribing Behavior. Med. Care 1995, 33, 139-144.